Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosei

Showing results (501-510 of 828) with videos related to

Pageof 83
Sort By:
Thyroid : Official Journal of the American Thyroid Association|November 21, 2015
A Double-Blind Placebo-Controlled Trial of Liquid Thyroxine Ingested at Breakfast: Results of the TICO StudyCarlo Cappelli, Ilenia Pirola, Linda Daffini, et al.
Nanoscale|March 17, 2022
Influence of Ti<sup>IV</sup> substitution on the properties of a Li<sub>1.5</sub>Al<sub>0.5</sub>Ge<sub>1.5</sub>(PO<sub>4</sub>)<sub>3</sub> nanofiber-based solid electrolyteAndrea La Monaca, Gabriel Girard, Sylvio Savoie, et al.
Cardiologia (Rome, Italy)|May 18, 1999
[Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension]E Agabiti-Rosei, E Giovannini, G Mancia, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1996
Vascular hypertrophy and remodeling in secondary hypertensionD Rizzoni, E Porteri, M Castellano, et al.
Journal of Hypertension|March 6, 2009
Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalaprilMichele M Ciulla, Roberta Paliotti, Arturo Esposito, et al.
Journal of Hypertension|November 1, 2002
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) studyCesare Cuspidi, M Lorenza Muiesan, Laura Valagussa, et al.
Nanoscale|December 20, 2017
Upconverting nanocomposites with combined photothermal and photodynamic effectsYue Huang, Artiom Skripka, Lucía Labrador-Páez, et al.
American Journal of Hypertension|April 1, 1991
Renal and hemodynamic effects of atrial natriuretic peptide infusion are not mediated by peripheral dopaminergic mechanismsM Castellano, M Beschi, E Agabiti-Rosei, et al.
Chemistry, an Asian Journal|June 13, 2013
Self-assembly of a halogenated molecule on oxide-passivated Cu(110)Mohamed El Garah, Josh Lipton-Duffin, Jennifer M MacLeod, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|September 1, 1996
Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trialsR B Devereux, E Agabiti-Rosei, B Dahlöf, et al.
Pageof 83

Showing results (501-510 of 828) with videos related to

Sort By:
Pageof 83
Thyroid : Official Journal of the American Thyroid Association|November 21, 2015
A Double-Blind Placebo-Controlled Trial of Liquid Thyroxine Ingested at Breakfast: Results of the TICO StudyCarlo Cappelli, Ilenia Pirola, Linda Daffini, et al.
Nanoscale|March 17, 2022
Influence of Ti<sup>IV</sup> substitution on the properties of a Li<sub>1.5</sub>Al<sub>0.5</sub>Ge<sub>1.5</sub>(PO<sub>4</sub>)<sub>3</sub> nanofiber-based solid electrolyteAndrea La Monaca, Gabriel Girard, Sylvio Savoie, et al.
Cardiologia (Rome, Italy)|May 18, 1999
[Arterial hypertension and heart diseases. Diagnostic-therapeutic guidelines. Joint Commission of the National Association of Hospital Cardiologists, the Italian Society of Cardiology and the Italian Society of Arterial Hypertension]E Agabiti-Rosei, E Giovannini, G Mancia, et al.
Hypertension (Dallas, Tex. : 1979)|November 1, 1996
Vascular hypertrophy and remodeling in secondary hypertensionD Rizzoni, E Porteri, M Castellano, et al.
Journal of Hypertension|March 6, 2009
Effects of antihypertensive treatment on ultrasound measures of myocardial fibrosis in hypertensive patients with left ventricular hypertrophy: results of a randomized trial comparing the angiotensin receptor antagonist, candesartan and the angiotensin-converting enzyme inhibitor, enalaprilMichele M Ciulla, Roberta Paliotti, Arturo Esposito, et al.
Journal of Hypertension|November 1, 2002
Comparative effects of candesartan and enalapril on left ventricular hypertrophy in patients with essential hypertension: the candesartan assessment in the treatment of cardiac hypertrophy (CATCH) studyCesare Cuspidi, M Lorenza Muiesan, Laura Valagussa, et al.
Nanoscale|December 20, 2017
Upconverting nanocomposites with combined photothermal and photodynamic effectsYue Huang, Artiom Skripka, Lucía Labrador-Páez, et al.
American Journal of Hypertension|April 1, 1991
Renal and hemodynamic effects of atrial natriuretic peptide infusion are not mediated by peripheral dopaminergic mechanismsM Castellano, M Beschi, E Agabiti-Rosei, et al.
Chemistry, an Asian Journal|June 13, 2013
Self-assembly of a halogenated molecule on oxide-passivated Cu(110)Mohamed El Garah, Josh Lipton-Duffin, Jennifer M MacLeod, et al.
Journal of Hypertension. Supplement : Official Journal of the International Society of Hypertension|September 1, 1996
Regression of left ventricular hypertrophy as a surrogate end-point for morbid events in hypertension treatment trialsR B Devereux, E Agabiti-Rosei, B Dahlöf, et al.
Pageof 83